US2011282037A1PendingUtilityA1

Antibody preparation

53
Assignee: WALDMANN HERMANPriority: Jul 21, 1998Filed: Jun 17, 2011Published: Nov 17, 2011
Est. expiryJul 21, 2018(expired)· nominal 20-yr term from priority
A61P 37/00C07K 2317/24A61K 38/00A61P 37/06C07K 16/2809C07K 2317/41A61P 35/00C07K 2319/00C07K 2317/565C07K 16/28
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An IgG antibody is provided having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. The novel antibody is capable of being expressed by mammalian cell expression systems at enhanced yields.

Claims

exact text as granted — not AI-modified
1 . An IgG antibody having a binding affinity for the CD3 antigen complex in which in the heavy chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 2, 4 and 6 and respective conservatively modified variants thereof and the light chain has a variable region framework together with at least one CDR selected from the amino acid sequences of SEQ ID No 8, 10 and 12 and respective conservatively modified variants thereof characterised in that the heavy chain variable region framework corresponds in sequence to the human type sequence and the light chain variable region framework includes one or more of the specific amino acids characteristic of the rodent type sequence. 
     
     
         2 - 43 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.